Q-omics provides the consensus-scored NOX4 profile across patient tissues and cancer cell-line models. NOX4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NOX4 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, NOX4 RNA expression shows 17,268 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where NOX4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOX4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOX4 survival associations across molecular data types. NOX4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOX4 RNA expression–survival associations across cancer types. High NOX4 expression shows unfavorable associations in ACC, STAD and LGG, but favorable associations in KIRP, SKCM and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for NOX4 RNA expression.
This table summarizes NOX4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NOX4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOX4 shows lower tumor expression in KIRP and higher tumor expression in HNSC, LUAD, COAD, THCA and LIHC. The HNSC box plot shows higher NOX4 RNA expression in tumor versus normal tissue (log2 FC = +1.948, t-test p < 0.001).
This table shows molecular features associated with NOX4 in patient tissues and cancer cell lines. In patient samples, NOX4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NOX4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
